Many human hemoglobin variants occur in heterozygotes; that is, the variant and normal hemoglobins are present in the same sample. In a procedure for rapidly identifying such variants by mass spectrometry, mutations that increase the mass by 1 Da require a special approach. One of the steps in this procedure involves digesting the denatured hemoglobin with trypsin and analyzing the resulting peptide mixture by mass spectrometry to identify the mutant peptide. Generally the mutant peptide ion can then be selected as the precursor and sequenced by tandem mass spectrometry to identify or confirm the mutation. However, with heterozygotes in which the mass of the variant is 1 Da higher than normal, the first isotope of the mutant peptide occurs at essentially the same mass as the second isotope of the normal peptide, precluding analysis of the mutant peptide on its own. Product ions from the second isotope of a peptide are doublets, 1 Da apart. The way in which the relative abundance of the components in these doublets varies with the elemental composition of the product ions was predicted from the isotopic abundance of the elements and agreed well with experimental data. These results were applied to the identification of a variant that increases the mass by 1 Da in a heterozygote—that is, β131 Gln→Glu, hemoglobin Camden.